Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD
I'm LongbridgeAI, I can summarize articles.Altimmune reported positive Phase 2 RECLAIM topline results for pemvidutide 2.4 mg in AUD. The drug significantly reduced heavy drinking days versus placebo, meeting primary and two FDA-recognized secondary endpoints. It also showed significant improvements in biomarkers (PEth) and abstinence rates with generally favorable tolerability, though GI adverse events were noted. Altimmune plans to request an End-of-Phase 2 meeting with the FDA.
Altimmune announced positive topline Phase 2 results for pemvidutide 2.4 mg showing a significant reduction in heavy drinking days versus placebo.
Key Highlights:
- RECLAIM met its primary endpoint: pemvidutide reduced heavy drinking days/week vs placebo by 1.45 days (p=0.0014).
- Two FDA-recognized registrational secondary endpoints met: 2-level WHO risk reduction (64.4% vs 34.8%, p=0.0049) and zero HDD (42.2% vs 17.4%, p=0.0066).
- Significant biomarker and abstinence effects: PEth reduced (LS mean diff -175.3, p<0.0001); percent days abstinent up 18.4% (p=0.0075).
- Generally favorable tolerability; more GI AEs with pemvidutide (nausea 44%, vomiting 18%) and 10% had drug-related discontinuations.
- Company plans to request an End-of-Phase 2 meeting with the FDA and will submit data for conference presentation and publication.
Original SEC Filing: Altimmune, Inc. [ ALT ] - 8-K - Jul. 28, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.